Top 100 Agencies: AgencyRx

Share this article:
The Cellmaster iPad game for Afinitor
The Cellmaster iPad game for Afinitor

AgencyRx president Michael Schreiber describes 2012 as a coming-of-age year for the agency. “We're about eight years old right now, so I guess in agency years that's adolescence,” he says, laughing, “and I feel like we're really coming into our adulthood and on the cusp of being a tier one agency—that's exciting.”

The agency has gone from being known as a CDM conflict shop to the second largest of the group, says Schreiber: “I think calling us a conflict shop is a little bit of a misnomer. We do handle some conflicts, but on the other hand we're a full-service agency pitching our own business. We're not just a conflict shop.”

In most coming-of-age stories, there are growing pains, and AgencyRx's was no different. Due to consolidation, AgencyRx lost some of its business with Novartis. “[They] consolidated their professional business, with agencies other than Omnicom, and so they slowly drifted away,” explains Schreiber. “That consolidation took a toll on us. There were some brands that we had since their inception like Exjade and Galvus. But that's how the consolidation trend goes.”

Just as AgencyRx saw a big name fall off its roster, it would win two significant pitches to finish off 2012. “We won a pitch for ParaGard, an IUD for women's health, and a product from Noven for treating menopause,” says Schreiber, “we grew our women's health portfolio.” The agency would also score wins from a new biopharmaceutical client, Keryx, and from Edward Lifesciences, for their heart valve technologies, at the start of 2013.

Schreiber attributes some of his agency's success to its “Lab Team Model,” their take on structuring teams: “So traditionally, you would have an account person with an art director and a copywriter leading your accounts, and then bring in supplemental disciplines when necessary,” he explains. “But what we've done is we give every brand a lead team that is equal parts creative, account, digital and strategic services. Each one of those brands has a dedicated member at the helm working side by side with the other disciplines.”

That model has led AgencyRx to a fast start in 2013, according to Schreiber, with the agency already seeing double-digit growth. Another shift for the Omnicom shop is part of a wider industry trend: the move away from primary care blockbusters to more specialty products.

“The days of the giant blockbuster are few and far between. We're not getting single products with multimillion-dollar budgets,” Schreiber points out. “We're looking at specialty products, and the kind of work we are doing for them is different, too. It's not necessarily the big launch campaign with multiple POAs. It's non-traditional work. Things like consulting or advocacy building through a medical group.  And it's often very targeted digital work so we can measure the ROI on it. It's a lot more granular than what we've seen in the past.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?